Concert Pharmaceuticals (CNCE +4.2%) has received a Notice of Allowance from the USPTO for a patent covering the composition of lead candidate CTP-543 and methods of treating alopecia areata with CTP-543.
Phase 3 studies should commence this year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.